Human papillomavirus vaccination at the first opportunity: An overview

• Type of Material: Article
• Authors: Robert Bednarczyk, Emory University; Noel T Brewer, University of North Carolina; Melissa B Gilkey, University of North Carolina; Sherri Zorn, Washington State HPV Free Taskforce; Rebecca B Perkins, Boston University; Kristin Oliver, Icahn Sch Med Mt Sinai; Debbie Saslow, American Cancer Society
• Language: English
• Date: 2023-05-21
• Publisher: TAYLOR & FRANCIS INC
• Publication Version: Final Published Version
• Copyright Statement: © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1080/21645515.2023.2213603
• Title of Journal or Parent Work: HUMAN VACCINES & IMMUNOTHERAPEUTICS
• Volume: 19
• Issue: 1
• Start Page: 2213603
• End Page: 2213603
• Grant/Funding Information: The work was supported by the National Cancer Institute [1R37CA234119].
• Keywords: Science & Technology; Immunology; adolescent; Human papillomavirus; HPV vaccination; Life Sciences & Biomedicine; HPV; Biotechnology & Applied Microbiology; vaccination recommendations
• Research Categories: Health Sciences, Public Health; Health Sciences, Epidemiology

Abstract

The Advisory Committee on Immunization Practices (ACIP) has recommended human papillomavirus (HPV) vaccination for adolescents in the United States since 2006. Though recommended at a similar time to the routine recommendations for adolescent tetanus, diphtheria, and acellular pertussis vaccination (Tdap) and quadrivalent meningococcal vaccination (MCV4), HPV vaccine uptake has consistently lagged behind these other adolescent vaccines. The ACIP recommends HPV vaccination at 11–12 y, with vaccination starting at 9 y of age included as an option that is routinely encouraged by the American Academy of Pediatrics and American Cancer Society. To support efforts to increase HPV vaccination at the first opportunity, this commentary summarizes the current HPV vaccination recommendations and available evidence regarding HPV vaccination starting at 9 y–including recent studies and trials documenting the effectiveness of HPV vaccination at 9 in supporting vaccine series completion, while providing future directions for research and implementation to improve HPV vaccination.